AGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Agilon Health (AGL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown some positive financial growth trends and hedge funds are buying, the ongoing class action lawsuits, lack of strong proprietary trading signals, and mixed analyst ratings suggest caution. The stock's recent price volatility and technical indicators also do not provide a clear long-term entry point.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 70.772. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near resistance levels (R1: 0.566, R2: 0.632). This suggests limited upside potential in the short term.
Hedge funds are significantly increasing their positions, with buying up 1326.49% last quarter. The company reported revenue growth of 3.09% YoY in Q4 2025 and has projected strong membership and revenue growth for 2026.
Multiple class action lawsuits alleging securities fraud and misleading financial statements. Analysts have downgraded price targets, citing high medical costs and increased costs for exited markets. The stock has a history of volatility, with a pre-market drop of -8.00% and a regular market gain of 18.92% in the last session.
In Q4 2025, revenue increased by 3.09% YoY to $1.57 billion. Net income improved by 78.54% YoY but remains negative at -$188.88 million. EPS also improved by 76.92% YoY but is still negative at -$0.46. Gross margin improved significantly but remains negative at -5.02%.
Jefferies views the new LEAD ACO model as a positive for Agilon but maintains a Hold rating. Bernstein lowered its price target from $1.40 to $0.88, citing increased costs and high prior period medical expenses. RBC Capital's upgrade to Outperform was for a different entity (AGL Energy), not Agilon Health.
